Xarleto | eHealth News | Page 2

The safety and efficacy of rivaroxaban treatment for nonvalvular atrial fibrillation in patients with active cancer is similar to the general population

Rivaroxaban OK for Stroke Prevention in Cancer Patients

HealthDay.com - Jul 12, 2017

Safety, efficacy in cancer patients similar to the general population

Rivaroxaban is associated with reduced risk of recurrent events among patients with venous thromboembolism in equipoise for continued anticoagulation

ACC: Rivaroxaban Beats Aspirin for Lower Risk of Recurrent VTE

HealthDay.com - Mar 20, 2017

Low dose cuts risk in equipoise for continued anticoagulation; rate of bleeding similar to aspirin

Rivaroxaban may pose a slightly greater risk of serious bleeding than dabigatran in patients with atrial fibrillation

Higher Bleeding Risk Seen With Rivaroxaban Versus Dabigatran

HealthDay.com - Oct 3, 2016

Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban

For patients with atrial fibrillation at moderate to high risk of stroke

DAPT Use Variable in Patients With A-Fib at Risk of Stroke

HealthDay.com - Aug 15, 2016

Dual antiplatelet therapy used in variable manner; most patients remain on study drug after PCI

12Page 2 of 2

Archives